US2015353643A1PendingUtilityA1
Anti-cd277 antibodies and uses thereof
Est. expirySep 24, 2033(~7.2 yrs left)· nominal 20-yr term from priority
C07K 16/2827C07K 2317/55C07K 2317/74C07K 2317/75A61K 40/4224A61K 40/32A61K 40/15A61K 40/11A61K 2239/38A61K 2239/31A61K 2239/48C07K 16/2818C07K 16/2896A61K 39/3955A61K 39/0011A61K 2039/505
39
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vγ9/Vδ2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.
Claims
exact text as granted — not AI-modified1 . A method of treatment comprising the step of administering to a patient in need thereof a therapeutically effective amount of an anti-CD277 antibody.
2 . The method according to claim 1 wherein said anti-CD277 antibody is an anti-CD277 antibody which:
activates the cytolytic function, cytokine production and proliferation of Vγ9/Vδ2 T cells, and/or
costimulates T cells together with CD3-TCR, and/or
costimulates T cells in addition to CD28-B7 costimulation, and/or
increases the activity and/or survival of monocytes and dendritic cells.
3 . The method according to claim 1 wherein said anti-CD277 antibody is an anti-CD277 antibody, which:
activates the cytolytic function, cytokine production and proliferation of Vγ9/Vδ2 T cells,
costimulates T cells together with CD3-TCR,
costimulates T cells in addition to CD28-B7 costimulation, and
increases the activity and/or survival of monocytes and dendritic cells.
4 . The method according to claim 1 wherein said anti-CD277 antibody is an anti-CD277 antibody obtainable from the hybridoma accessible under CNCM deposit number I-4401 or I-4402.
5 . The method according to claim 1 wherein said anti-CD277 antibody is an antibody comprising the following CDRs:
Aminoacid sequence
H-CDR1
RYYLY (SEQ ID NO: 7)
H-CDR2
EINPNNGGTKFNEKFKS
(SEQ ID NO: 8)
H-CDR3
EDDYDGTPDAMDY
(SEQ ID NO: 9)
L-CDR1
HASQNINLWLS
(SEQ ID NO: 10)
L-CDR2
RASNLHT (SEQ ID NO: 11)
L-CDR3
QQGHSYPYT (SEQ ID NO: 12)
or
Aminoacid sequence
H-CDR1
RYYMY (SEQ ID NO: 27)
H-CDR2
EINPNNGGTKFNEKFKN (SEQ ID
NO: 28)
H-CDR3
EDDYDGTPFAMDY (SEQ ID
NO: 29)
L-CDR1
HASQNINVWLS (SEQ ID NO: 30)
L-CDR2
KASNLHT (SEQ ID NO: 31)
L-CDR3
QQGQTYPYT (SEQ ID NO: 32)
6 . The method according to claim 1 wherein said patient suffers from a cancer or a chronic infection.
7 . A method for treating a cancer or a chronic infection comprising the step of administering:
a) an anti-CD277 antibody; and b) a vaccine for the treatment of a cancer or a chronic infection.
8 . The method according to claim 1 wherein said anti-CD277 antibody is an anti-CD277 antibody which inhibits the cytolytic function, cytokine production and proliferation of Vγ9/Vδ2 T cells.
9 . The method according to claim 1 wherein said anti-CD277 antibody is an anti-CD277 antibody obtainable from the hybridoma accessible under CNCM deposit number I-4403 or an antibody having the same 6 CDRs as the antibody obtainable from the hybridoma accessible under CNCM deposit number I-4403.
10 . The method according to claim 1 wherein said anti-CD277 antibody is an antibody comprising the following CDRs:
Aminoacid sequence
H-CDR1
GFAIN (SEQ ID NO: 47)
H-CDR2
LIYPYNGGTTYSQRFKG
(SEQ ID NO: 48)
H-CDR3
RRDGYSWFAY
(SEQ ID NO: 49)
L-CDR1
RASESVENYGIIFMN
(SEQ ID NO: 50)
L-CDR2
SASNQGS (SEQ ID NO: 51)
L-CDR3
QQSKEAPFT
(SEQ ID NO: 52)
11 . The method according to claim 1 wherein said patient suffers from an autoimmune disease, transplantation rejection or a graft versus host disease.Join the waitlist — get patent alerts
Track US2015353643A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.